Среднесрочные и отдаленные результаты высокой тибиальной остеотомии у больных первичным и вторичным остеоартритом коленного сустава с варусной деформацией

The most common operation for knee osteoarthritis (OA) is total knee arthroplasty (TKA); however, the latter is associated with the development of severe complications. This was the reason for the revival of the interest of orthopedic traumatologists in high tibial osteotomy (HTO), the essence of which is to transfer the load away from the affected medial part of the knee joint (KJ) to the intact lateral one.Objective: to evaluate the medium- and long-term results of open-wedge (OW) HTO in primary and secondary I–III stage knee OA.Patients and methods. The Laboratory of Orthopedic Rheumatology and Rehabilitation, V.A. Nasonova Research Institute of Rheumatology, performed 10 OW HTOs in 9 patients in 2005 to 2009 and 21 more OW HTOs in 19 patients in 2014 to 2018 (a total of 31 operations). The male/female ratio was 2.5:1. The mean age of the patients was 57.6±12.5 years; the body mass index (BMI) was 28.5±3.6 kg/m2 ; the correction angle was 11.7±2.5°. Preoperative planning was performed using the Miniaci method; the X-ray stage of knee OA was evaluated according to the Kellgren–Lawrence classification. OW HTO was carried out. For assessment of its results, the investigators determined the degree of pain using a visual analogue scale (VAS) and the KJ status by the Knee Society Score (KSS) scale. The results were assessed at one (n=31), 3.5±0.6 (n=28), and 8.5±1.3 (n=10) years.Results and discussion. There was a tendency to worsen surgical results over time. The mean VAS values for pain at 1, 3.5, and 8.5 years were as follows: 9.8±10.3; 21.2±16.2 and 38±15.5 mm, respectively. In the same periods, the KSS functional scores were 83.6±14.8, 85.2±12.6, and 80.5±14.2; the objective scores were 80.7±8.5, 75.2±12.7, and 67.8±16.3. There was a strong correlation between the severity of pain and the functional and objective KSS scores (-0.78, -0.81 years, and -0.91 at 1, 3.5, and 8.5 years, respectively; p<0.05). At 3.5±0.6 years, the survival rate after OW HTO was 96.6%. None of the patients examined at 8.5±1.3 years after OW HTO needed TKA. The surgical result was studied in 2 patients at 14 years; one patient underwent TKA, the other refused surgical intervention, the result was satisfactory.Conclusion. OW HTO has limited indications for use. However, in patients who are allowed to undergo this operation, pain syndrome can be relieved, by maintaining and/or improving KJ function; in most cases, TKA can be delayed for more than 10 years. Самой распространенной операцией при остеоартрите (ОА) коленного сустава (КС) является тотальное эндопротезирование (ТЭ), однако оно сопряжено с развитием тяжелых осложнений. Это послужило причиной возрождения интереса травматологовортопедов к высокой тибиальной остеотомии (ВТО), суть которой заключается в перенесении нагрузки с пораженного медиального отдела КС на интактный латеральный.Цель исследования – оценить среднесрочные и отдаленные результаты открывающей угол (ОУ) ВТО при первичном и вторичном ОА КС I–III стадии.Пациенты и методы. В лаборатории ревмоортопедии и реабилитации НИИР им. В.А. Насоновой с 2005 по 2009 г. было выполнено 10 ОУ ВТО у 9 пациентов, а с 2014 по 2018 г. – еще 21 ОУ ВТО у 19 больных (всего 31 операция). Соотношение мужчин и женщин – 2,5:1. Средний возраст больных составил 57,6±12,5 года, индекс массы тела (ИМТ) – 28,5±3,6 кг/м2 , угол коррекции – 11,7±2,5°. Предоперационное планирование проводили по методу Миниаци, рентгенологическую стадию ОА КС оценивали по классификации Kellgren–Lawrence. Выполняли ОУ ВТО. Для оценки результата операции определяли выраженность боли по визуальной аналоговой шкале (ВАШ) и состояние КС по шкале Knee Society Score (KSS). Результаты оценивали через год (n=31), 3,5±0,6 года (n=28) и 8,5±1,3 года (n=10).Результаты и обсуждение. Выявлена тенденция к ухудшению результатов операции с течением времени. Средние значения боли по ВАШ через 1 год, 3,5 и 8,5 года были следующие: 9,8±10,3; 21,2±16,2 и 38±15,5 мм соответственно. Функциональный счет по KSS за те же периоды составил: 83,6±14,8; 85,2±12,6 и 80,5±14,2, объективный счет – 80,7±8,5; 75,2±12,7 и 67,8±16,3. Была выявлена сильная связь выраженности боли с функциональным и объективным счетом KSS (-0,78 через 1 год, -0,81 через 3,5 года и -0,91 через 8,5 лет; р<0,05). Выживаемость результатов ОУ ВТО через 3,5±0,6 года составила 96,6%. Ни один из больных, осмотренных через 8,5±1,3 года после ОУ ВТО, в ТЭ КС не нуждался. У 2 больных результаты операции были изучены через 14 лет: одной пациентке было выполнено ТЭ КС, другая от операции отказывается, результаты удовлетворительные.Выводы. ОУ ВТО имеет ограничения. Однако у пациентов, которым может быть проведена эта операция, удается купировать болевой синдром при сохранении и/или улучшении функции КС; отдалить в большинстве случаев сроки проведения ТЭ КС более чем на 10 лет.

Эффективность локальных инъекций обогащенной тромбоцитами плазмы крови при синдроме сдавления ротаторов плеча

Chronic shoulder pain caused by shoulder impingement syndrome (SIS) is a common pathology that leads to worse quality of life and disability. The local administration of platelet-rich plasma (PRP) is a promising treatment for SIS.Objective: to evaluate the efficiency of subacromial injection of PRP in chronic shoulder pain caused by SIS.Patients and methods. The investigation enrolled 30 patients (13 women and 17 men; mean age, 45.8±14.1 years) with chronic shoulder pain lasting ≥3 months after rotator tendons injury confirmed by ultrasound and/or magnetic resonance imaging and inefficiency of previously medical therapy. All the patients received three subacromial injections of 5 ml of PRP at a 7-day interval. The investigators assessed the course of pain during movement (100-mm visual analogue scale (VAS)) and functional ability according to the ASES and CSC questionnaires at baseline and 1, 3 and 6 months after treatment.Results and discussion. During the treatment, there was a considerable improvement in all indicators. At baseline and 1 and 3 months, the mean pain severity measured on VAS was 49.3±10.3, 32.4±21.3, and 20.6±21.3 mm, respectively; in this case, the positive effect persisted at 6-month follow-up: 10 [0; 30] mm (p<0.001). The mean ASES values were 59.5±11.5, 75.9±17.4, 82.6±17.6, and 86.7±17.1 (p<0.001) and the mean CSC scores were 72.3±14.1, 81.0±16.2, 88.5±16.1, and 92.8±16.2 (p<0.001), respectively. There were no serious adverse reactions.Conclusion. Subacromial injection of PRP is an effective and safe treatment for chronic shoulder pain associated with SIS.Хроническая боль в плече, вызванная синдромом сдавления ротаторов плеча (ССРП), – распространенная патология, которая приводит к ухудшению качества жизни и потере трудоспособности. Перспективным методом лечения ССРП является локальное введение обогащенной тромбоцитами плазмы крови (ОТП).Цель исследования – оценить эффективность субакромиального введения ОТП при хронической боли в плече, вызванной ССРП.Пациенты и методы. В исследование включено 30 пациентов (13 женщин и 17 мужчин, средний возраст – 45,8±14,1 года) с хронической болью в плече длительностью ≥3 мес, возникшей после повреждения сухожилий ротаторов плеча, подтвержденного данными УЗИ и/или магнитно-резонансной томографии, и неэффективностью проводимой ранее консервативной терапии. Всем больным выполнено субакромиальное введение ОТП 5 мл по 3 инъекции с интервалом в 7 дней. Оценивались динамика боли при движении (визуальная аналоговая шкала – ВАШ, 100 мм) и функциональная способность по опросникам ASES и CSC исходно и через 1, 3 и 6 мес после лечения.Результаты и обсуждение. На фоне лечения отмечалось значительное улучшение всех показателей. Средняя выраженность боли по ВАШ исходно и через 1 и 3 мес составила 49,3±10,3; 32,4±21,3 и 20,6±21,3 мм соответственно, при этом положительный эффект сохранялся и через 6 мес наблюдения: 10 [0; 30] мм (p<0,001). Средние значения ASES составили 59,5±11,5; 75,9±17,4; 82,6±17,6; 86,7±17,1 (p<0,001), а CSC – 72,3±14,1; 81,0±16,2; 88,5±16,1; 92,8±16,2 (p<0,001) соответственно. Серьезных нежелательных реакций не отмечено.Выводы. Субакромиальное введение ОТП является эффективным и безопасным методом лечения хронической боли в плече при ССРП

Оценка эффективности внутрисуставного введения препарата гиалуроновой кислоты высокой степени очистки при остеоартрите коленного сустава в реальной клинической практике

Knee osteoarthritis (kOA) is a common cause of turning for medical advice, associated with chronic pain and disability. One of the methods of OA treatment is the local administration of hyaluronic acid (HA) drugs.Objective: to evaluate the effectiveness of intra-articular (IA) administration of highly purified HA (Armaviskon Plus) in kOA.Patients and methods. The study group consisted of 58 patients (74.1% women and 25.9% men, aged 59.5±11.8 years) with kOA, experiencing moderate/severe pain (≥40 mm on a visual analogue scale, VAS). All patients received IA injection of HA Armaviskon Plus (2 ml of a 1.5% solution), 2 injections with an interval of 7 days. The effectiveness criterion was the dynamics of pain at rest and during movement (VAS 0-100 mm) and the function of the knee joint according to a numerical rating scale (NRS 0-100 points) 2 weeks, 1 and 3 months after administration of therapy.Results and discussion. During the treatment, there was a significant improvement in all indicators. The average severity of pain during movement at baseline, after 2 weeks, 1 and 3 months was 50 [40; 60], 30 [20; 40], 15 [0; 30], 20 [0; 30] mm (p<0.001), at rest 20 [10; 40], 5 [0; 20], 0 [0; 20], 10 [0; 20] mm (p<0.05) by VAS. The average values of functional indicators were 40 [10; 60], 10 [0; 40], 20 [0; 40], 10 [10; 30] scores according to the NRS. A decrease in non-steroidal anti-inflammatory drugs demand was recorded: 67.1% of patients were initially taking them, after 3 months – 36.1% (p<0.001). No serious adverse reactions were noted.Conclusion. IA administration of HA is an effective and safe method for the treatment of kOA. Armaviskon Plus, a highly purified high-molecular- weight HA drug, has shown good results in pain reduction and improvement of function in knee OA as well as a favorable safety profile, which makes it possible to recommend its use in real clinical practice.Остеоартрит (ОА) коленного сустава (КС) – распространенная причина обращения за медицинской помощью, с которой связаны хроническая боль, потеря трудоспособности и инвалидизация. Одним из методов лечения ОА является локальное введение препаратов гиалуроновой кислоты (ГлК).Цель исследования – оценка эффективности внутрисуставного (в/с) введения препарата ГлК высокой степени очистки (Армавискон Плюс) при ОА КС.Пациенты и методы. Исследуемую группу составили 58 пациентов (74,1% женщин и 25,9% мужчин, возраст 59,5±11,8 года) с ОА КС, испытывающих умеренную/выраженную боль (≥40 мм по визуальной аналоговой шкале, ВАШ). Всем больным проводилось в/с введение препарата Армавискон Плюс (2 мл 1,5% раствора) по 2 инъекции с интервалом в 7 дней. Критерием эффективности была динамика боли в покое и при движении (ВАШ 0–100 мм) и функции КС по числовой рейтинговой шкале (ЧРШ, 0–100 баллов) через 2 нед, 1 и 3 мес после курса терапии.Результаты и обсуждение. На фоне лечения отмечалось значительное улучшение всех показателей. Средняя выраженность боли при движении исходно, через 2 нед, 1 и 3 мес составила 50 [40; 60], 30 [20; 40], 15 [0; 30], 20 [0; 30] мм (p<0,001), в покое – 20 [10; 40], 5 [0; 20], 0 [0; 20], 10 [0; 20] мм (p<0,05) по ВАШ. Средние значения функциональных показателей равнялись 40 [10; 60], 10 [0; 40], 20 [0; 40], 10 [10; 30] баллам по ЧРШ. Зафиксировано снижение потребности в приеме нестероидных противовоспалительных препаратов: если исходно их принимали 67,1% больных, то через 3 мес – уже 36,1% (p<0.001). Серьезных нежелательных реакций не отмечено.Заключение. В/с введение ГлК является эффективным и безопасным методом лечения ОА КС. Препарат высокомолекулярной ГлК высокой степени очистки Армавискон Плюс показал хороший результат в отношении уменьшения боли и улучшения функции при ОА КС, а также благоприятный профиль безопасности, что позволяет рекомендовать его использование в реальной клинической практике

ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with limited comorbidities, while for patients older than 65 years, the BR regimen is more often considered as less toxic one. According to published data, 46% of patients with newly diagnosed CLL have comorbidities. Moreover, high-risk patients with del(17p) and/or TP53 mutation do not have response on immunochemotherapy (ICT) most often. Thus, about 1/2 of the patients cannot be treated or will not respond to standard ICT regimens. Targeted therapy with Brutons tyrosine kinase (BTK) inhibitors is an important option of the first-line treatment of patients with CLL. Acalabrutinib is a highly selective second-generation BTK inhibitor that does not inhibit EGFR, ITK or TEC targets. Acalabrutinib in combination with obinutuzumab or as monotherapy can be considered as a highly effective and safe option of the first line of CLL therapy. Based on the hight selectivity of the agent, acalabrutinib can be considered as the preferable option for patients who are not eligible for ICT, including patients with commodities, such as cardiovascular diseases or risk factors for their development

Medium- and long-term results of high tibial osteotomy in patients with primary and secondary knee osteoarthritis with varus deformity

The most common operation for knee osteoarthritis (OA) is total knee arthroplasty (TKA); however, the latter is associated with the development of severe complications. This was the reason for the revival of the interest of orthopedic traumatologists in high tibial osteotomy (HTO), the essence of which is to transfer the load away from the affected medial part of the knee joint (KJ) to the intact lateral one.Objective: to evaluate the medium- and long-term results of open-wedge (OW) HTO in primary and secondary I–III stage knee OA.Patients and methods. The Laboratory of Orthopedic Rheumatology and Rehabilitation, V.A. Nasonova Research Institute of Rheumatology, performed 10 OW HTOs in 9 patients in 2005 to 2009 and 21 more OW HTOs in 19 patients in 2014 to 2018 (a total of 31 operations). The male/female ratio was 2.5:1. The mean age of the patients was 57.6±12.5 years; the body mass index (BMI) was 28.5±3.6 kg/m2 ; the correction angle was 11.7±2.5°. Preoperative planning was performed using the Miniaci method; the X-ray stage of knee OA was evaluated according to the Kellgren–Lawrence classification. OW HTO was carried out. For assessment of its results, the investigators determined the degree of pain using a visual analogue scale (VAS) and the KJ status by the Knee Society Score (KSS) scale. The results were assessed at one (n=31), 3.5±0.6 (n=28), and 8.5±1.3 (n=10) years.Results and discussion. There was a tendency to worsen surgical results over time. The mean VAS values for pain at 1, 3.5, and 8.5 years were as follows: 9.8±10.3; 21.2±16.2 and 38±15.5 mm, respectively. In the same periods, the KSS functional scores were 83.6±14.8, 85.2±12.6, and 80.5±14.2; the objective scores were 80.7±8.5, 75.2±12.7, and 67.8±16.3. There was a strong correlation between the severity of pain and the functional and objective KSS scores (-0.78, -0.81 years, and -0.91 at 1, 3.5, and 8.5 years, respectively; p<0.05). At 3.5±0.6 years, the survival rate after OW HTO was 96.6%. None of the patients examined at 8.5±1.3 years after OW HTO needed TKA. The surgical result was studied in 2 patients at 14 years; one patient underwent TKA, the other refused surgical intervention, the result was satisfactory.Conclusion. OW HTO has limited indications for use. However, in patients who are allowed to undergo this operation, pain syndrome can be relieved, by maintaining and/or improving KJ function; in most cases, TKA can be delayed for more than 10 years

Use of first metatarsophalangeal joint chondroplasty with the autologous matrix-induced chondrogenesis technique for the treatment of patients with hallux rigidus: immediate results

Currently, there are a lot of different surgical treatments for hallux rigidus, such as cheilectomy; first metatarsal osteotomies, hemiarthroplasty, arthroplastry and arthrodesis of the first metatarsophalangeal joint (MTPJ), and all of them have both advantages and disadvantages. To date, there is no single approach to choosing a method of surgical treatment of hallux rigidus. The autologous matrix-induced chondrogenesis (AMIC) technique is known to be quite successfully used for the treatment of osteochondral defects in the knee, hip, and ankle joints.Objective: to study the immediate results of first MTPJ chondroplasty using the AMIC technique in patients with hallux rigidus.Subjects and methods. As of now, MTPJ chondroplasty using the AMIC technique has been performed at the Nasonova Research Institute of Rheumatology in the first 9 patients with hallux rigidus. The surgery was made on both sides in one patient; there were accordingly a total of 10 above operations. The patients' mean age was 42.2+19.5 (range 20—71) years. During the examination, the investigators determined the range of motion in the first MTPJ, the intensity of pain on a visual analogue scale (VAS); foot status according to the American Orthopedic Foot and Ankle Society (AOFAS) scale; as well as the foot function index (FFI) and the functional condition of the foot and ankle (FA) joints according to VAS-FA. Prior to surgery, all the patients experienced significantly restricted motions in the first MTPJ. The median range of motion in the first MTPJ was 20°; Pain intensity was 70 mm; the AOFAS score was 52; FFI — 6.4; the VAS-FA — 4.1. First MTPJ chondroplasty was performed according to the AMIC technique using the Chondro-Gide and Aesculap Novocart Basic collagen matrices. The results of surgical treatment were assessed at 3, 6, and 12 months postoperatively.Results and discussion. Just 3 months after surgery, there was a pronounced significant reduction in first MTPJ pain. Its median decreased from 70 to 27.5         mm. After 6 months, there were also positive changes; the median pain was 10 mm. It remained at a level of 10 mm by the end of the first year of the observation. The median AOFAS scores increased from 52 to 78.5 and 90 at 3 and 6 months after surgery, respectively, and remained at the same level at 12 months. The median FFI decreased from 6.4 to 2.3, 1.1, and 0.8 at 3, 6, and 12 months following chondroplasty, respectively. The median VAS-FA scores were 8.1, 9.3, and 9.6 at 3, 6, and 12 months after chondroplasty. At 3 months postoperatively, the range of first MTPJ motion also increased significantly: its median rose from 20° to 60°; it was 65° at 6 months and increased to 67.5° at 12 months. First MTPJ chondroplasty with the AMIC technique in these patients resulted in positive changes that were maximal at 3 months after the surgery: the median pain decreased by 42.5      mm; AOFAS, FFI, and VAS-FA scores increased by 26.5, 2.1, and 4.0, respectively. Of great importance is also the increase in first MTPJ motion range, the median of which rose by 40° at 3 moths. The positive changes also persisted 6 months postoperatively. During this period, there was a further decrease in the median pain by 17.5 mm and increases in the median AOFAS, FFI, and VAS-FA scores by 12.5, 1.2, and 1.2, respectively. At 12 months of the follow up, the achieved improvement remained; however, the number of observations at this stage does not allow for adequate statistical analysis.Conclusion. The immediate results of the performed operations showed that first MTPJ chondroplasty using a collagen matrix can be a rather effective surgical treatment that makes it possible to relieve pain and to significantly improve quality of life in patients with hallux rigidus. A more complete evaluation of the efficiency of first MTPJ chondroplasty using the AMIC technique will be provided by studying the medium-term and long-term outcomes of the surgery

HIGH TIBIAL OSTEOTOMY IN THE TREATMENT OF PATIENTS WITH STAGE II–III OF KNEE OSTEOARTHRITIS. IMMEDIATE RESULTS AND FACTORS INFLUENCING THE OUTCOME

Knee osteoarthritis (OA) is the most common form of OA. Medical treatment for OA does not provide the desired effect in a significant proportion of patients. With greater rates of knee OA and its rejuvenation, high tibial osteotomy (HTO) that can prolong the period of the patient’s own knee joint (KJ) function and postpone or completely avoid total knee arthroplasty is becoming increasingly relevant. Objective: to investigate the efficiency of HTO for stage II–III knee OA and the impact of age, body mass index (BMI), and correction angle on the immediate result of surgery. Subjects and methods. Thirty-five HTOs were carried out in 32 patients in 2003 to 2016. The male and female ratio was approximately 2:1. The patients’ mean age was 59.0±13.1 years; BMI, 29.04±3.57 kg/m2 , correction angle, 12.5±2.78°. A visual analog scale (VAS) was used to assess pain; and the Knee Society Score (KSS) was employed to rate the functional and objective status of the KJ. The degenerative process was graded using the Kellgren–Lawrence radiographic classification. Results and discussion. HTO proved to be effective in patients with both Stage II and III knee OA. A year after surgery, there was a substantial reduction in VAS pain (from 72.27±11.79 to 7.72±6.62 mm) and an improvement in functional and objective KSS scores (from 43.66±11.5 and 54.39±11.77 to 86.51±10.86 and 81.93±6.65 mm, respectively). The results were excellent (36.4%), good (57.6%), and satisfactory (6%). No X-ray signs of progressive OA were revealed one year after surgery. BMI affected immediate results (Spearman correlation coefficient = -0.34; p < 0.05). Thus, HTO has been established to be more effective in Stage II knee OA than in its Stage III. Age and correction angle do not affect immediate results while higher BMI is associated with worse outcomes and complications

Efficiency of local injections of platelet-rich plasma in shoulder impingement syndrome

Chronic shoulder pain caused by shoulder impingement syndrome (SIS) is a common pathology that leads to worse quality of life and disability. The local administration of platelet-rich plasma (PRP) is a promising treatment for SIS.Objective: to evaluate the efficiency of subacromial injection of PRP in chronic shoulder pain caused by SIS.Patients and methods. The investigation enrolled 30 patients (13 women and 17 men; mean age, 45.8±14.1 years) with chronic shoulder pain lasting ≥3 months after rotator tendons injury confirmed by ultrasound and/or magnetic resonance imaging and inefficiency of previously medical therapy. All the patients received three subacromial injections of 5 ml of PRP at a 7-day interval. The investigators assessed the course of pain during movement (100-mm visual analogue scale (VAS)) and functional ability according to the ASES and CSC questionnaires at baseline and 1, 3 and 6 months after treatment.Results and discussion. During the treatment, there was a considerable improvement in all indicators. At baseline and 1 and 3 months, the mean pain severity measured on VAS was 49.3±10.3, 32.4±21.3, and 20.6±21.3 mm, respectively; in this case, the positive effect persisted at 6-month follow-up: 10 [0; 30] mm (p<0.001). The mean ASES values were 59.5±11.5, 75.9±17.4, 82.6±17.6, and 86.7±17.1 (p<0.001) and the mean CSC scores were 72.3±14.1, 81.0±16.2, 88.5±16.1, and 92.8±16.2 (p<0.001), respectively. There were no serious adverse reactions.Conclusion. Subacromial injection of PRP is an effective and safe treatment for chronic shoulder pain associated with SIS

COMPLICATIONS OF OPENING WEDGE HIGH TIBIAL OSTEOTOMY

Opening wedge high tibial osteotomy (OWHTO) is a surgical treatment option for osteoarthritis (OA) of the knee with a predominant lesion of its medial segment, which can restore the mechanical axis of the lower limb, transfer load from affected medial to intact lateral part of knee joint, and thus slow OA progression, reduce or even abolish pain, prolong the function of the patient’s own knee joint, and delay total knee arthroplasty. Like any surgical intervention, OWHTO can be responsible for common, local, and specific surgical complicationsObjective: to investigate complications from OWHTO and to determine the impact of the design of short spacer plates, bone graft materials and/or bone substitutes, as well as age, body weight and wedge angle correction on the development of complications in patients undergoing this surgery.Subjects and methods. Twenty-eight OWHTOs were performed in 26 patients in 2003 to 2016. The male and female ratio was approximately 2:1. The patients’ mean age was 58.1±11.24 years; body mass index, 28.56±3.61 kg/m2; correction angle, 11.8±2.4°. Fixation was carried out using short spacer plates of three different designs: Puddu plate I, II, and Osteomed. Bone grafting was performed applying an iliac wing autograft or a biodegradable bone substitute (β-tricalcium phosphate) as rectangular blocks, or Inject. Bone grafting was not done when the wedge size was <10 mm.Results and discussion. Twelve complications were diagnosed in 11 of the 28 (39.25%) cases. Of these, there were 8 cases of pain at the site of the implanted plate, three intra-articular fractures of the lateral tibial plateau, and one case of impaired polymerization of liquid β-tricalcium phosphate. There were no statistically significant relationships between the parameters investigated and the development of complications.Conclusion. Clamp-associated complications develop with the same frequency regardless of the design of short spacer plates. The use of liquid β-tricalcium phosphate should be avoided in closing wedge osteotomy. Age, body weight, and the magnitude of a correction angle are unassociated with the development of complications in OWHTO

Efficiency of local hyaluronic acid injections in subacromial impingement syndrome

Chronic shoulder pain associated with subacromial impingement syndrome (SIS) is a common pathology that causes suffering and disability. One of the treatments for SIS is the local injection of hyaluronic acid (HA) preparations.Objective: to evaluate the efficiency of subacromial injection of HA in chronic shoulder pain associated with SIS.Subjects and methods. A study group consisted of 31 patients (48.4% of women and 51.6% of men; mean age 53.8±15.2 years) with chronic shoulder pain (>3 months) that had occurred after rotator tendon injury confirmed by ultrasound and/or magnetic resonance imaging. All the patients received two subacromial injections of 40 mg HA in 2 ml at a 7-day interval. The efficacy criteria were the changes of pain during movement (100-mm visual analogue scale (VAS)) and functional ability according to the ASES and CSC questionnaires at 1, 3 and 6 months.Results and discussion. During the treatment, there was a considerable improvement in all measures. At baseline and 1, 3, and 6 months, the mean pain severity measured on VAS was 60.0±20.0, 40.0±25.4, 31.6±26.0, and 32.2±26.5 mm (p<0.001), the mean ASES scores were 53.64±16.43, 70.08±17.70, 86.13±12.86, and 82.69±27.88 (p<0.001); the mean CSC scores were 52.38±21.1, 66.26±20.83, 73.9±24.14, and 76.1±25.02 (p<0.001) respectively. No serious adverse events were noted.Conclusion. Subacromial injection of HA is an effective and safe treatment for chronic shoulder pain associated with SIS